Management of prostate cancer in Asia: Resource-stratified guidelines from the Asian Oncology Summit 2013

The Lancet Oncology

Volumn 14, Issue 12, 2013, Pages

  Williams, Scott ^a   Chiong, Edmund ^b   Lojanapiwat, Bannakij ^c   Umbas, Rainy ^d   Akaza, Hideyuki ^e  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d UNIVERSITY OF INDONESIA   (Indonesia)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; ESTRAMUSTINE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; KETOCONAZOLE; MITOXANTRONE; PLACEBO; PREDNISONE; RADIUM CHLORIDE RA 223; SAMARIUM 153; STRONTIUM 89; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; ASIA; BONE DISEASE; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE SCINTISCANNING; BRACHYTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CHINA; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS DEVELOPMENT; CRYOTHERAPY; DIARRHEA; DRUG FATALITY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HEALTH EDUCATION; HOT FLUSH; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; JAPAN; JAW OSTEONECROSIS; LYMPH NODE DISSECTION; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; PHILIPPINES; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE FRACTIONATION; RADIOACTIVITY; REVIEW; RISK FACTOR; SIDE EFFECT; SINGAPORE; SOUTH KOREA; SURVIVAL TIME; THAILAND; UNSPECIFIED SIDE EFFECT; VOMITING; WATCHFUL WAITING;

ASIA; DELIVERY OF HEALTH CARE; HEALTH RESOURCES; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; MALE; MEDICAL ONCOLOGY; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84886687434     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70451-0     Document Type: Review

References (117)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893. 2817.
2. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012, 61:1079-1092.
3. Lim GH, Chow KY, Lee HP Singapore cancer trends in the last decade. Singapore Med J 2012, 53:3-9.
4. Hsing AW, Tsao L, Devesa SS International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000, 85:60-67.
5. Cullen J, Elsamanoudi S, Brassell SA, et al. The burden of prostate cancer in Asian nations. J Carcinog 2012, 11:7.
6. Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH, Chen J Changing trends of prostate cancer in Asia. Aging Male 2004, 7:120-132.
7. Chia SE, Tan CS, Lim GH, Sim X, Lau W, Chia KS Incidence, mortality and five-year relative survival ratio of prostate cancer among Chinese residents in Singapore from 1968 to 2002 by metastatic staging. Ann Acad Med Singapore 2010, 39:466-471.
8. Sim HG, Cheng CW Changing demography of prostate cancer in Asia. Eur J Cancer 2005, 41:834-845.
9. Sim HG, Lim KH, Tay MH, Chong KT, Chiong E Guidelines on management of prostate cancer. Ann Acad Med Singapore 2013, 42:190-199.
10. Asia consensus statement: prostate cancer 2011, NCCN clinical practice guidelines in oncology, National Comprehensive Cancer Network, Fort Washington, PA.
11. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010, 8:162-200.
12. Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer 2008, 113(suppl 8):2221-2243.
13. Carducci MA, Carroll PR Multidisciplinary management of advanced prostate cancer: changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials. Urology 2005, 65(suppl 5):18-22.
14. Aizer AA, Paly JJ, Zietman AL, et al. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol 2012, 30:3071-3076.
15. Valdagni R, Albers P, Bangma C, et al. The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology. Eur J Cancer 2011, 47:1-7.
16. Sternberg CN, Krainer M, Oh WK, et al. The medical management of prostate cancer: a multidisciplinary team approach. BJU Int 2007, 99:22-27.
17. Fitzpatrick JM, Anderson J, Sternberg CN, et al. Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. Crit Rev Oncol Hematol 2008, 68(suppl 1):S9-22.
18. Fuchsjager MH, Shukla-Dave A, Hricak H, et al. Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy. BJU Int 2009, 104:315-320.
19. Sala E, Akin O, Moskowitz CS, et al. Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology 2006, 238:929-937.
20. Mullerad M, Hricak H, Wang L, Chen HN, Kattan MW, Scardino PT Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology 2004, 232:140-146.
21. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009, 101:374-383.
22. Albertsen PC, Hanley JA, Fine J 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095-2101.
23. Glass AS, Cooperberg MR, Meng MV, Carroll PR Role of active surveillance in the management of localized prostate cancer. J Natl Cancer Inst Monogr 2012, 2012:202-206.
24. Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 2013, 105:1050-1058.
25. Klotz L Active surveillance for prostate cancer: patient selection and management. Curr Oncol 2010, 17(suppl 2):S11-S17.
26. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010, 28:126-131.
27. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009, 27:4300-4305.
28. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004, 172:910-914.
29. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001, 28:555-565.
30. Bianco FJ, Scardino PT, Eastham JA Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology 2005, 66(5 suppl):83-94.
31. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011, 364:1708-1717.
32. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-213.
33. Walsh PC Anatomic radical prostatectomy: evolution of the surgical technique. J Urol 1998, 160:2418-2424.
34. Menon M, Shrivastava A, Kaul S, et al. Vattikuti Institute prostatectomy: contemporary technique and analysis of results. Eur Urol 2007, 51:648-657.
35. Joslyn SA, Konety BR Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006, 68:121-125.
36. Masterson TA, Bianco FJ, Vickers AJ, et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006, 175:1320-1324.
37. Mattei A, Fuechsel FG, Bhatta Dhar N, et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 2008, 53:118-125.
38. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008, 54:344-352.
39. Briganti A, Karnes JR, Da Pozzo LF, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009, 55:261-270.
40. Liss MA, Lusch A, Morales B, et al. Robot-assisted radical prostatectomy: 5-year oncological and biochemical outcomes. J Urol 2012, 188:2205-2210.
41. Parsons JK, Bennett JL Outcomes of retropubic, laparoscopic, and robotic-assisted prostatectomy. Urology 2008, 72:412-416.
42. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009, 302:1557-1564.
43. Gardiner RA, Yaxley J, Coughlin G, et al. A randomised trial of robotic and open prostatectomy in men with localised prostate cancer. BMC Cancer 2012, 12:189.
44. Ficarra V, Novara G, Rosen RC, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012, 62:405-417.
45. Ficarra V, Novara G, Ahlering TE, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012, 62:418-430.
46. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002, 95:281-286.
47. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005, 366:572-578.
48. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009, 181:956-962.
49. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27:2924-2930.
50. Stephenson AJ, Bolla M, Briganti A, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012, 61:443-451.
51. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
52. Kuban D Long-Term Results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
53. Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomised phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24:1990-1996.
54. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294:1233-1239.
55. Gill S, Thomas J, Fox C, et al. Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol 2011, 6:145.
56. Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 83:125-129.
57. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005, 6:831-850.
58. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103-108.
59. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011, 306:2359-2366.
60. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23:6132-6138.
61. Yeoh E, Fraser R, McGowan R, et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinomaearly results of a Phase III randomized trial. Int J Radiat Oncol Biol Phys 2003, 55:943-955.
62. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012, 82:e17-e24.
63. Proust-Lima C, Taylor JM, Secher S, et al. Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 2011, 79:195-201.
64. Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman RD Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. J Oncol Pract 2012, 8(3 suppl):e31s-e37s.
65. Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13:43-54.
66. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006, 64:518-526.
67. King CR, Brooks JD, Gill H, Presti JC Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:877-882.
68. Konski A, Speier W, Hanlon A, Beck JR, Pollack A Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?. J Clin Oncol 2007, 25:3603-3608.
69. Morris WJ, Keyes M, Palma D, et al. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Urology 2009, 73:860-865.
70. Critz FA, Benton JB, Shrake P, Merlin ML 25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy. J Urol 2013, 189:878-883.
71. Crook J, Fleshner N, Roberts C, Pond G Long-term urinary sequelae following 125iodine prostate brachytherapy. J Urol 2008, 179:141-145.
72. Williams S, Millar J, Duchesne G, Dally M, Royce P, Snow R Factors predicting for urinary morbidity following iodine transperineal prostate brachytherapy. Radiother Oncol 2004, 73:33-38.
73. Robinson JW, Moritz S, Fung T Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002, 54:1063-1068.
74. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261.
75. Kotecha R, Yamada Y, Pei X, et al. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy 2013, 12:44-49.
76. Khor R, Duchesne G, Tai KH, et al. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys 2013, 85:679-685.
77. Sullivan L, Williams SG, Tai KH, et al. Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol 2009, 91:232-236.
78. Cooperberg MR, Hinotsu S, Namiki M, et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009, 27:4306-4313.
79. Akaza H, Carroll P, Cooperberg MR, Hinotsu S Fifth joint meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management. Jpn J Clin Oncol 2012, 42:226-236.
80. Cooperberg M, Hinotsu S, Namiki M, Carroll P, Akaza H 724. Trans-Pacific variation in outcomes for men treated with primary androgen deprivation therapy for localized prostate cancer. J Urol 2013, 189:e297. (abstr).
81. Ueno S, Namiki M, Fukagai T, Ehara H, Usami M, Akaza H Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol 2006, 13:1494-1500.
82. Akaza H, Hinotsu S, Usami M, et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009, 115:3437-3445.
83. Akaza H, Hinotsu S, Cooperberg MR, et al. Sixth joint meeting of J-CaP and CaPSURE: a multinational perspective on prostate cancer management and patient outcomes. Jpn J Clin Oncol 2013, 43:756-766.
84. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373:301-308.
85. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011, 378:2104-2111.
86. Mason MD, Parulekar W, Sydes MR, et al. Final analysis of intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110). Proc Am Soc Clin Oncol 2013, abstr 4509.
87. Polascik TJ, Mayes JM, Mouraviev V From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer. Oncology 2008, 22:900-906.
88. Rosoff JS, Savage SJ, Prasad SM Salvage radical prostatectomy as management of locally recurrent prostate cancer: outcomes and complications. World J Urol 2013, published online Jan 29. 10.1007/s00345-013-1029-z.
89. Mendenhall WM, Henderson RH, Hoppe BS, Nichols RC, Mendenhall NP Salvage of locally recurrent prostate cancer after definitive radiotherapy. Am J Clin Oncol 2012, published online Dec 12. 10.1097/COC.0b013e31824be3b4.
90. Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2007, 67:1106-1112.
91. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991, 67:502-508.
92. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000, 132:566-577.
93. Crawford ED, Tombal B, Miller K, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 2011, 186:889-897.
94. Sciarra A, Abrahamsson PA, Brausi M, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013, 5:722-730.
95. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012, 367:895-903.
96. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
97. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002, 168:2439-2443.
98. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999, 17:2506-2513.
99. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000, 355:1491-1498. Prostate Cancer Trialists' Collaborative Group.
100. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002, 95:361-376.
101. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
102. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
103. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007, 13:6396-6403.
104. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
105. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
106. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197.
107. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004, 22:1025-1033.
108. Vogelzang N, Parker C, Nilsson S, et al. Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA). Proc Am Soc Clin Oncol 2013, abstr 11.
109. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
110. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
111. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012, 379:39-46.
112. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
113. Wirth M. Can Zometa prevent bone metastases in high risk prostate cancer patients? First Results of the Zometa European Study (ZEUS). European Association of Urology 28th Annual Congress; Milan, Italy; March 15-19, 2013; abstr.
114. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-1764.
115. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991, 27:954-958.
116. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004, 63:940-945.
117. Living with & beyond cancer: taking action to improve outcomes 2013, Department of Health, Macmillan Cancer SupportMacmillan Cancer Support, NHS ImprovementNHS Improvement, Department of Health, London.